Jeffrey Zonder, MD

Jeffery Zonder, MD, is the leader of the Multiple Myeloma Sub-Committee at Barbara Ann Karmanos Cancer Institute and a professor of medicine in the Department of Hematology and Oncology at Wayne State University School of Medicine.

Articles

Strategic Sequencing in Advanced Mycosis Fungoides: Choosing Between Immunomodulatory, HDAC, and Targeted Therapies

June 25th 2025

Panelists discuss how individualized treatment plans must consider disease location, drug access, comorbidities, and newer therapies like HDAC inhibitors and immune checkpoint inhibitors, while emphasizing the importance of managing expectations and monitoring side effects.

Advanced-Stage Mycosis Fungoides: Navigating Treatment Decisions Amid a Complex Therapeutic Landscape

June 25th 2025

Panelists discuss how treatment goals and selection for advanced-stage cutaneous T-cell lymphoma depend on disease compartmentalization, with therapies like brentuximab vedotin and mogamulizumab being used based on specific disease characteristics and toxicity profiles.

Monitoring Response in Early-Stage Mycosis Fungoides & Importance of Patient Education

June 18th 2025

Panelists discuss how careful patient monitoring, education, and expectation management are essential in evaluating the effectiveness of skin-directed therapies, emphasizing routine assessments, treatment compliance, and the need for patience due to varying response times.

Other Treatment Strategies in Early-Stage Mycosis Fungoides: TSEBT, Localized Radiotherapy, Phototherapy and Combination Approach

June 18th 2025

Panelists discuss how electron therapy—both spot and total skin electron beam—is used to manage extensive or refractory skin involvement and palliate symptoms in CTCL patients.

Collaborating With Dermatologists: Coordinating Skin-Directed Therapy and Follow-Up in CTCL

June 10th 2025

Panelists discuss how multidisciplinary collaboration between dermatologists and oncologists helps optimize personalized treatment plans by integrating skin-directed and systemic therapies.

Managing Early-Stage Mycosis Fungoides: Treatment Goals and Topical Therapy Selection

June 10th 2025

Panelists discuss how therapeutic goals for early-stage CTCL focus on symptom control with skin-directed therapies, avoiding systemic chemotherapy due to long-term toxicity and poor outcomes.

Understanding CTCL Staging: From Limited Mycosis Fungoides to Advanced Disease

June 4th 2025

Panelists discuss how early-stage CTCL is defined using TNMB staging criteria, the typical presentation of patients at various stages, and the implications for treatment approaches.

Cutaneous T-Cell Lymphoma Insights: Distinguishing MF and SS, and Recognizing Early-Stage Clues

June 4th 2025

Panelists discuss how CTCL is diagnosed, distinguished between Mycosis Fungoides and Sézary Syndrome, and why early-stage disease is often misdiagnosed due to its resemblance to benign skin conditions.

Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma

May 21st 2025

Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.

Dr Zonder on the Importance of Early Screening for Myeloma Among High-Risk Patients

April 18th 2025

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Dr Zonder on the Epidemiology of Multiple Myeloma

April 7th 2025

Jeffrey Zonder, MD, discusses the current epidemiological landscape of multiple myeloma in the United States.

Dr Zonder on the Need for Increased Awareness in Multiple Myeloma

March 24th 2025

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple Myeloma

February 20th 2024

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.

Dr Zonder on Unmet Needs to be Addressed in Multiple Myeloma

February 13th 2024

Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.

Clinical Pearls and Future Directions in AL Amyloidosis

January 22nd 2024

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

January 22nd 2024

Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.

Adverse Event Management in AL Amyloidosis

January 15th 2024

Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

January 15th 2024

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Birtamimab Safety Profile in the VITAL Study

January 8th 2024

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

January 8th 2024

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

x